Barclays
ABOS icon

Barclays’s Acumen Pharmaceuticals ABOS Stock Holding History

Barclays’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$106K Buy
39,655
+8,976
+29% +$22.2K ﹤0.01% 4018
2026
Q1 		$72.4K Buy
30,679
+688
+2% +$1.75K ﹤0.01% 4168
2025
Q4 		$63.3K Hold
29,991
– – ﹤0.01% 4696
2025
Q3 		$51.3K Hold
29,991
– – ﹤0.01% 4761
2025
Q2 		$34.8K Sell
29,991
-42,274
-58% -$45.4K ﹤0.01% 4759
2025
Q1 		$79.5K Sell
72,265
-20,817
-22% -$29.7K ﹤0.01% 4475
2024
Q4 		$160K Buy
93,082
+31,085
+50% +$74.8K ﹤0.01% 4406
2024
Q3 		$154K Buy
61,997
+40,551
+189% +$110K ﹤0.01% 4426
2024
Q2 		$51.9K Sell
21,446
-25,864
-55% -$82.3K ﹤0.01% 4199
2024
Q1 		$192K Sell
47,310
-37
-0.1% -$139 ﹤0.01% 4137
2023
Q4 		$182K Buy
47,347
+24,922
+111% +$74K ﹤0.01% 4459
2023
Q3 		$93.1K Sell
22,425
-2,969
-12% -$18.3K ﹤0.01% 3625
2023
Q2 		$122K Sell
25,394
-558
-2% -$2.67K ﹤0.01% 3487
2023
Q1 		$105K Sell
25,952
-8,509
-25% -$44.4K ﹤0.01% 4148
2022
Q4 		$186K Buy
34,461
+300
+0.9% +$2.02K ﹤0.01% 3880
2022
Q3 		$342K Buy
34,161
+27,437
+408% +$157K ﹤0.01% 2898
2022
Q2 		$32K Sell
6,724
-5,093
-43% -$19.1K ﹤0.01% 4214
2022
Q1 		$46K Buy
+11,817
New +$64.3K ﹤0.01% 4145

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $1.12B AUM 41.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Barclays's ABOS Position: Q2 2026 in Review

Barclays increased its Acumen Pharmaceuticals (ABOS) stake by 29% in Q2 2026, buying an estimated $22.2K and bringing the position to 39,655 shares worth $106K. The position accounts for ﹤0.01% of the portfolio, ranked #4018.

Barclays first reported a position in ABOS in Q1 2022 and has held it in 18 quarters since. The position peaked at $342K in Q3 2022. 96 funds tracked by Wall St. Rank hold ABOS as of Q2 2026.

  • Barclays held 39,655 shares of Acumen Pharmaceuticals worth $106K as of Q2 2026.
  • Barclays bought 8,976 Acumen Pharmaceuticals shares in Q2 2026, an estimated $22.2K.
  • Acumen Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4018 holding.
  • Barclays first reported a position in Acumen Pharmaceuticals in Q1 2022 and has held it in 18 quarters since.
  • Barclays's Acumen Pharmaceuticals position peaked at $342K in Q3 2022.
  • 96 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.